22ZA Stock Overview
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Zealand Pharma A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr.17.10 |
| 52 Week High | kr.21.00 |
| 52 Week Low | kr.9.20 |
| Beta | 1.01 |
| 1 Month Change | 0% |
| 3 Month Change | 3.64% |
| 1 Year Change | -6.56% |
| 3 Year Change | -44.82% |
| 5 Year Change | n/a |
| Change since IPO | 51.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| 22ZA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -5.1% | -2.0% |
| 1Y | -6.6% | -21.1% | -0.3% |
Return vs Industry: 22ZA exceeded the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: 22ZA underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 22ZA volatility | |
|---|---|
| 22ZA Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 22ZA has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 22ZA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 203 | Adam Steensberg | www.zealandpharma.com |
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management.
Zealand Pharma A/S Fundamentals Summary
| 22ZA fundamental statistics | |
|---|---|
| Market cap | €1.36b |
| Earnings (TTM) | -€150.45m |
| Revenue (TTM) | €37.33m |
36.3x
P/S Ratio-9.0x
P/E RatioIs 22ZA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 22ZA income statement (TTM) | |
|---|---|
| Revenue | kr.277.51m |
| Cost of Revenue | kr.108.42m |
| Gross Profit | kr.169.09m |
| Other Expenses | kr.1.29b |
| Earnings | -kr.1.12b |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -21.73 |
| Gross Margin | 60.93% |
| Net Profit Margin | -403.04% |
| Debt/Equity Ratio | 100.6% |
How did 22ZA perform over the long term?
See historical performance and comparison